The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 8.50
Ask: 10.00
Change: 0.00 (0.00%)
Spread: 1.50 (17.647%)
Open: 9.25
High: 9.25
Low: 9.25
Prev. Close: 9.25
NBB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Surrender and Granting of Options

9 Oct 2023 07:00

RNS Number : 0525P
Norman Broadbent PLC
09 October 2023

Norman Broadbent plc

("Norman Broadbent" or the "Company")

Surrender of existing options

and

Grant of new options

Surrender of existing options

Norman Broadbent (AIM: NBB), a leading London quoted Executive Search and Interim Management firm offering a diversified portfolio of integrated Leadership Acquisition & Advisory Services, announces that, on 6 October 2023, Peter Searle, Non-Executive Chair, surrendered for no consideration 1.0 million options over the Company's ordinary shares of 1p each ("Ordinary Shares") which were granted pursuant to the Company's Long Term Incentive Scheme ("LTIP") on 18 March 2022, Kevin Davidson, Chief Executive Officer, surrendered for no consideration 2,548,148 options over Ordinary Shares which were granted pursuant to the LTIP between 18 March 2022 and 28 July 2023, Mehr Malik, Chief Financial Officer, surrendered for no consideration 1.7 million options over Ordinary Shares which were granted pursuant to the LTIP on 28 July 2023, and Sean Bergin, who is a Person Discharging Managerial Responsibilities ("PDMR") surrendered for no consideration 1.7 million options over Ordinary Shares which were granted pursuant to the LTIP between 18 March 2022 and 28 July 2023.

The above surrenders of existing options have been made to amend the terms of the LTIP, to standardise the terms for all participants and to align the terms of the LTIP with the Board's expectations.

Grant of new options

Subsequently, each of Peter Searle, Kevin Davidson, Mehr Malik and Sean Bergin has, in accordance with the LTIP established by resolution of the Board of Directors on 6 October 2023, been granted on 6 October 2023 (the "Date of Grant ") options over Ordinary Shares exercisable at nil pence per Ordinary Share ("Options"). The following table sets out details of the Options that have been granted to both the Company's Executive Directors and one PDMR:

Name of Individual

Director/PDMR

Number of Share Price Vesting Options granted

Number of EBITDA Vesting Options granted

Total Number of Options granted

Percentage of the Company's Existing Issued Shares Under Option held

Percentage of the Company's Fully Diluted Share Capital held*

Kevin Davidson

CEO

1,274,074

1,274,074

2,548,148

4.1%

3.4%

Mehr Malik

CFO

850,000

850,000

1,700,000

2.8%

2.3%

Sean Bergin

COO and PDMR

850,000

850,000

1,700,000

2.8%

2.3%

Peter Searle

Non-Executive Chair

500,000

500,000

1,000,000

1.6%

1.4%

Total

3,474,074

3,474,074

6,948,148

11.3%

9.4%

*assuming that no further Ordinary Shares are issued between the date of this announcement and exercise of the Options.

25 per cent. of the Options vest immediately on the Date of Grant and the remaining options are granted over a period of three years and vest subject to two sets of performance criteria:

· 50 per cent. of the vested Options are exercisable on a scaled basis following the price of an Ordinary Share achieving an average of between 10p and 19p over any three-month period prior to 30 June 2026 ("Share Price Vesting Options"); and

· The remaining 50 per cent. of the vested Options are exercisable on a scaled basis following the achievement by the Company of audited EBITDA in the range of greater than £0.5 million to £1.25 million in any financial year from the Date of Grant to 31 December 2025 ("EBITDA Vesting Options").

Following the grant of the Options, there are 12,148,148 options over Ordinary Shares outstanding representing 19.7 per cent. of the Company's issued share capital. At the date of this announcement, the Company has 61,817,543 Ordinary Shares in issue.

The FCA notification, made in accordance with the requirements of the UK Market Abuse Regulation is appended further below.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Peter Searle

Kevin Davidson

Chair

CEO

Mehr Malik

CFO

Sean Bergin

COO

2

Reason for the notification

a)

Position/status

See 1a) above

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Norman Broadbent Plc

b)

LEI

213800E5YN5TA934XA23

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Options over ordinary shares of £0.01 each in Norman Broadbent Plc

Identification code (ISIN) for Norman Broadbent Plc ordinary shares: GB00B3VF4Y66

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Name

Price(s)

Volume(s)

Peter Searle

Kevin Davidson

nil

nil

1,000,000

2,548,148

Mehr Malik

nil

1,700,000

Sean Bergin

nil

1,700,000

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

Options put in place as of 06 October 2023

f)

Place of the transaction

Outside a trading venue

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For further information, please contact:

Norman Broadbent plc +44 (0) 20 7484 0000

Kevin Davidson, CEO

Mehr Malik, CFO

Shore Capital (Nominated Adviser and Broker) 020 7408 4090

Tom Griffiths / Tom Knibbs (Corporate Advisory)

Henry Willcocks (Corporate Broking)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFSMESAEDSESS
Date   Source Headline
25th Apr 20247:00 amRNSQ1 2024 Trading Update
24th Apr 20247:00 amRNSSmall Cap Awards nomination
15th Apr 20243:18 pmRNSNotification of major holdings
8th Apr 202412:11 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20244:01 pmRNSNotification of major holdings
28th Mar 20247:00 amRNSPosting of ARA & Notice of AGM
27th Mar 20247:00 amRNSFinal Results
26th Mar 20244:07 pmRNSNotification of major holdings
20th Mar 20241:36 pmRNSNotice of Results & Investor Presentation
18th Mar 20244:33 pmRNSNotification of major holdings
18th Mar 20244:04 pmRNSNotification of major holdings
12th Mar 20243:33 pmRNSAIM Rule 17 Schedule Two (g) Update
22nd Jan 20245:32 pmRNSNotification of Major Holdings
16th Jan 20247:00 amRNSTrading Update
21st Nov 202310:06 amRNSNotification of Major Holdings
20th Nov 202310:45 amRNSDirector/PDMR shareholding
15th Nov 20239:54 amRNSNotification of Major Holdings
15th Nov 20239:43 amRNSNotification of Major Holdings
10th Nov 20237:00 amRNSDirector/PCA Dealing
9th Nov 20232:25 pmRNSDirector/PDMR Shareholding
2nd Nov 20238:43 amRNSConversion Of Outstanding Convertible Loan Notes
12th Oct 20237:00 amRNSQ3 2023 Trading Update
10th Oct 202311:03 amRNSNotification of Major Holdings
9th Oct 20237:00 amRNSSurrender and Granting of Options
28th Jul 20237:00 amRNSGrant of Options
24th Jul 20237:00 amRNSInterim Results
11th Jul 20237:00 amRNSH1 2023 Trading Update
30th Jun 20237:00 amRNSSAYE Option Plan & Director Holding
29th Jun 20234:28 pmRNSResult of AGM
5th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSDirectorate changes
31st May 20237:00 amRNSFinal Results
22nd May 20237:00 amRNSQ1 2023 Trading Update
19th May 202312:55 pmRNSPartial Repayment of Convertible Loan Note
24th Jan 20237:00 amRNSTrading Update
10th Jan 20237:00 amRNSDirectorate Change
17th Nov 20224:42 pmRNSTR-1: Notification of major holdings
14th Nov 20227:00 amRNSIssue of Equity
1st Nov 20227:00 amRNSUpdate and Change of Board role
10th Oct 20225:30 pmRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSDirector Share Purchase
23rd Aug 20227:00 amRNSDirectorate Change
16th Aug 20227:00 amRNSInterim Results
29th Jul 20227:00 amRNSChange of Adviser
20th Jul 20224:08 pmRNSDirector/PDMR Dealing
11th Jul 20227:00 amRNSTrading Update
29th Jun 20223:15 pmRNSDirector/PDMR Shareholding
23rd Jun 202212:14 pmRNSResult of AGM
7th Jun 20228:59 amRNSHolding(s) in Company
25th May 20227:00 amRNSFinal 2021 Results and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.